Along with the rapidly growing use of anti-PD-1 or PD-L1 antibodies in the treatment of late-stage malignancies, cases of anti-PD-1/PD-L1-induced psoriasis have been gradually reported [223]. Here, PDCD1 is linked to psoriasis.